TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02576223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine hydrochloride
Description: Ropivacaine injected perineural at the suprascapular nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: Saline injected perineural at the suprascapular nerve.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PCA-pump
Description: PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA-pump
Description: PCA (Patient controlled analgesia) pump with the following settings:~Age \> 70 years or weight \< 60 kg: bolus dose 2,5 mg i.v. morphine, 15 minutes lockout Age \< 70 years and weight \> 60 kg: bolus dose 5 mg i.v. morphine, 15 minutes lockout Lockout time 15 minutes.
Study: NCT04152226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. Lividum
Description: Investigational Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. Lividum
Description: Investigational Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: J. Lividum
Description: Investigational Product
Study: NCT02749539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapy program
Description: active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy program
Description: active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
Study: NCT01658748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS
Description: Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Description: Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
Study: NCT01658748

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS
Description: Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
Study: NCT02579460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cessation of Acid Suppressing Medications
Description: Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
Study: NCT02622009

Intervention type: PROCEDURE
Intervention: BRONCHOSCOPIC PROCEDURE
Description: After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
Study: NCT03304561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Description: traditional ACL rehabilitation program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-over training
Description: Cross-over training addition to the traditional rehabilidation
Study: NCT03741465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The SFP technique
Description: The USG, and the 5-point NRS evaluation in the SFP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The ASP technique
Description: The USG, and the 5-point NRS evaluation in the ASP
Study: NCT00120016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary counseling
Description: telephone counseling
Study: NCT01813396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization plus massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization/shoulder physical activity guide
Study: NCT05212558

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo respiratory muscle training
Description: Unloaded respiratory muscle training plus conventional respiratory exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training plus conventional respiratory exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory muscle training
Description: Combined inspiratory and expiratory muscle training in the same respiratory cycle plus conventional respiratory exercises.
Study: NCT03102554

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Return of Genetic Results
Description: The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
Study: NCT04954508

Intervention type: DIAGNOSTIC_TEST
Intervention: The hug-up test
Description: It is a new physical test used to detect supraspinatus tear

Intervention type: DIAGNOSTIC_TEST
Intervention: EC test
Description: It is a traditional physical test used to detect supraspinatus tear

Intervention type: DIAGNOSTIC_TEST
Intervention: FC test
Description: It is a traditional physical test used to detect supraspinatus tear

Intervention type: DIAGNOSTIC_TEST
Intervention: Neer impingement sign
Description: It is a traditional physical test used to detect supraspinatus tear

Intervention type: DIAGNOSTIC_TEST
Intervention: Hawkins-Kennedy impingement sign
Description: It is a traditional physical test used to detect supraspinatus tear

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic arthroscopy
Description: The arthroscopic operation involved complete inspection of the supraspinatus. Supraspinatus tears were categorized as fullthickness tears (FTTs), which were classified as small (≤1 cm), moderate (≤3 cm), large (≤5 cm), and massive (\>5 cm), on the basis of the largest dimension, and partial-thickness tears (PTTs), which were classified as bursal-sided, articular-sided,and intra-tendinous. Other combined diseases including acromioclavicular joint derangement, infraspinatus lesions, subscapularis lesions, superior labrum anterior and posterior (SLAP) lesions, biceps disorders, and Bankart lesions were recorded as well to assess the specificity of the tests.
Study: NCT01067677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaclopramide
Description: 0.5 mg/kg for rescue after PONV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 0.1 mg/kg (max 4 mg0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: 0.25 mg/kg (max 25 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: equal volume (5 ml)as experimental rescue medications
Study: NCT03761927

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid without NR enabled
Description: Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(1)
Description: Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid with NR(2)
Description: Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
Study: NCT01091675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
Study: NCT02721875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study: NCT02337868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001
Description: HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001
Description: HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001
Description: HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
Study: NCT00729872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG011
Description: Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
Study: NCT02337868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HydroVax-001
Description: HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
Study: NCT00348712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, 4 mg once or twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled human insulin
Description: Treat-to-target dose titration scheme, inhalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Tablets, 2000 mg/day.
Study: NCT02840708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Study: NCT03483896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daylight Intervention
Description: Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
Study: NCT00430716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral, 20 mg, tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 1 mg, tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 5 mg, tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: oral 20 mg, tid
Study: NCT02263469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study: NCT00729872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG011
Description: Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG011
Description: Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
Study: NCT02794753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Game
Study: NCT03589508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person sessions: ABCP_P
Description: 6 weekly sessions of alcohol prevention conducted in person.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video conference sessions: ABCP_T
Description: 6 weekly sessions of alcohol prevention conducted by video conference.
Study: NCT02978573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartiva
Description: Cartiva Synthetic Cartilage Implant
Study: NCT03699826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS for tinnitus
Description: Targeted stimulation to decrease tinnitus symptom severity.
Study: NCT03056989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Inhalation solution twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Inhalation solution twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Inhalation solution twice daily for 7 days.
Study: NCT03324776

Intervention type: DRUG
Group type: OTHER
Intervention: Afrezza Inhalant Product
Description: Mealtime Ultra-Rapid Acting Insulin
Study: NCT00651924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IVR-based Cognitive-behavior therapy
Description: Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
Study: NCT00790946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 80 to 160 mg
Study: NCT02552368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IpsiHand Device
Description: Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
Study: NCT02908919

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: The quality of bowel preparation, which is checked during colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: The quality of bowel preparation, which is checked during colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: The quality of bowel preparation, which is checked during colonoscopy
Study: NCT01356160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-5885
Description: tablet, 30 mg QD
Study: NCT01312636

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Data will be collected at the baseline visit and approximately once a year until end of study.
Study: NCT02673515

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternate day fasting
Description: Subjects are requested to fast every other day. Calorie free fluids are allowed.
Study: NCT03616977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 U-200
Description: Administered SC
Study: NCT01356160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: tablet, 200 mg QD
Study: NCT03616977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014 U-100
Description: Administered SC
Study: NCT02733055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posturographic evaluation
Description: subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
Study: NCT00982995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
Study: NCT03580668

Intervention type: DRUG
Intervention: B/F/TAF
Description: B/F/TAF administered in accordance with the approved product monograph
Study: NCT03580005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate HCl ERCT
Description: methylphenidate HCl ERCT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Match Quillichew ERCT
Study: NCT02882529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
Study: NCT01356160

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a
Description: (solution for injection) 180 µg/week

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a
Description: (solution for injection) 180 µg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study: NCT02882529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.